The Smart Strategy: Subdividing M1 Stage And Aiming Remission For Target Nasopharyngeal Carcinoma Patients With Metachronous Metastasis.

Lujun Shen,Peihong Wu,Yunfei Xia,Wang Li,Chen Chen
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.6034
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:6034 Background: Metastatic nasopharyngeal carcinoma (mNPC) varied greatly from potentially curable to incurable. This study set out to identify the target patients with chance of cure through extensive M1 stage subdivision and treatment response assessment. Methods: 1172 NPC patients with metachronous metastasis from three medical centers in Southern China were retrospectively analyzed (916 pts in derivation dataset; 256 pts in validation dataset). Various metastatic features were assessed, including involvement of specific locations, n of metastatic locations and n of metastatic lesions. A new nomenclature system for precise M staging was designed based on the independent prognostic factors. The best treatment response was assessed based on RECIST 1.1 or the modified RECIST criteria. Results: Multivariate analysis in derivation cohort showed that n of metastatic lesions, n of metastatic locations, liver involvement, bone involvement, together with age, UICC N stage, local recurrence, were independent prognostic factors for overall survival (OS). Subdividing the population by n of metastatic lesions and n of metastatic locations could result in subgroups with highly significant differences in OS. The external validation by two independent datasets showed congruent results. A new nomenclature system (M [n of locations]-Location [n of lesions in location]; B, bone; L, lung, H, liver, N, node) was designed, our data showed that mNPC patients with isolate metastatic lesion (M1-B1, M1-L1, M1-H1, M1-N1), and those with two lesions in liver only (M1-H2) had high rates of complete remission (CR) or complete surgical resection (cSR), and 3-year OS after treatment (CR+cSR, > 30%; 3-yr OS, > 50%); for patients with more than three metastatic lesions in specific location (M1-Bm, M1-Hm) or multiple-location metastasis, the treatment response was generally poor, and the rates of cSR and 3-yr OS were low (CR, < 4%; cSR, 0%; 3-yr OS, < 30%). Conclusions: The SMART strategy could serve as a powerful tool in identifying the mNPC patients with chance of cure. More trials are needed to evaluate the feasibility and significance of achieving complete remission among the target patients.
What problem does this paper attempt to address?